| AUSFTA | KORUS | TPP | ||
---|---|---|---|---|---|
Signed / Implemented year | 2004 / 2005 | 2007 / 2012 | 2018 / 2018 | ||
Subjects | Annex 2-C - Pharmaceuticals | Side letters PBS | Chapter 5 – Pharmaceutical products and medical devices | Chapter 26 – Transparency and Anticorruption | Annex 26-A Transparency and Procedural Fairness for Pharmaceutical Products and Medical Devices |
Composition | 6 provisions and 580 words | 4 provisions and 251 words | 8 provisions and 1731 words | 3 sections (definitions, transparency, anti-corruption), 12 provisions, 3136 words | 5 provisions and 2072 words |
Principles | 1: Agreed Principles |  | 1: General provisions | – | 2: Principles |
Value for money (innovation) | – |  | 2: Access to innovation | – | – |
Transparency | 2: Transparency | 4 provisions are related with transparency | 3: Transparency | 2: Publication 3: Administrative Proceedings 4: Review and Appeal 5: Provision of Information | 3: Procedural Fairness |
Others | 3: Medicines Working Group 4: Regulatory Cooperation 5: Dissemination of Information 6: Definitions | Â | 4: Dissemination of Information 5: Ethical Business Practices 6: Regulatory Cooperation 7: Medicines and medical devices committee 8: Definitions | 1: Definitions | 1: Definitions 4: Dissemination of Information to Health Professionals and Consumers 5: Consultation |